Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Authors:

Abstract
No abstract available
Funding Information
  • Biogen

This publication has 29 references indexed in Scilit: